Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MARAVAI LIFESCIENCES HOLDINGS, INC.MRVI · Entity 4291 | Chief Financial Officer | September 30, 2026 | October 02, 2026 |
| NUVASIVE INCNUVA · Entity 110002 | CFO | March 01, 2019 | March 05, 2019 |
| Profusa, Inc.PFSA · Entity 2740 | Director | January 26, 2026 | January 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MARAVAI LIFESCIENCES HOLDINGS, INC.
Report date September 30, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 418,021 |
Reported balance
After 2026-09-30 transaction · row 1
1 source rowRow 1 · 2026-09-30 · Tax withholding · Disposed 5,465 · Balance 418,021 F1: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock unit awards held by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock unit awards held by the reporting person.
NUVASIVE INC
Report date March 01, 2019 · Filed March 05, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| RSUsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 12,398 |
Reported balance
After 2019-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-03-01 · Grant · Acquired 12,398 · Balance 12,398 F1: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2: This RSU award was granted to the Reporting Person on March 1, 2019. In accordance with the terms of the RSU award, the award will vest in full on March 1, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.
F2: This RSU award was granted to the Reporting Person on March 1, 2019. In accordance with the terms of the RSU award, the award will vest in full on March 1, 2022.
Profusa, Inc.
Report date January 26, 2026 · Filed January 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.35 · Expires 2036-01-26 | Direct | 221,794 |
Reported balance
After 2026-01-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-26 · Grant · Acquired 221,794 · Balance 221,794 F1: Represents an inaugural director award of options to purchase common stock. The options vest in three equal annual increments over a period of three years from the closing of the business combination between the Issuer (formerly known as NorthView Acquisition Corp.) and Profusa, Inc. (the "Closing"). |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.35 · Expires 2036-01-26 | Direct | 52,866 |
Reported balance
After 2026-01-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-26 · Grant · Acquired 52,866 · Balance 52,866 F2: Represents an annual director award of options to purchase common stock. The options vest on the first anniversary of the Closing. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an inaugural director award of options to purchase common stock. The options vest in three equal annual increments over a period of three years from the closing of the business combination between the Issuer (formerly known as NorthView Acquisition Corp.) and Profusa, Inc. (the "Closing").
F2: Represents an annual director award of options to purchase common stock. The options vest on the first anniversary of the Closing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2026 Filed Oct 2, 2026 02:02 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | Tax withholdingClass A Common Stock | 5,465 | $7.65 | $41,807.25 |
DisclosureSEC source: 0001600301-26-000008 · wk-form4_1790892148.xml · nonDerivative · entry 1 Asarpota Rajesh · CIK 0001600301 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 418,021 F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock unit awards held by the reporting person. Read SEC document |
| August 31, 2026 Filed Sep 1, 2026 22:21 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | Tax withholdingClass A Common Stock | 5,465 | $7.68 | $41,971.20 |
DisclosureSEC source: 0001600301-26-000006 · wk-form4_1788301262.xml · nonDerivative · entry 1 Asarpota Rajesh · CIK 0001600301 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 423,486 F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock unit awards held by the reporting person. Read SEC document |
| July 30, 2026 Filed Aug 3, 2026 20:42 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | Tax withholdingClass A Common Stock | 5,465 | $6.59 | $36,014.35 |
DisclosureSEC source: 0001600301-26-000004 · wk-form4_1785789741.xml · nonDerivative · entry 1 Asarpota Rajesh · CIK 0001600301 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 428,951 F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock unit awards held by the reporting person. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 00:30 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | Tax withholdingClass A Common Stock | 65,584 | $6.39 | $419,081.76 |
DisclosureSEC source: 0001600301-26-000002 · wk-form4_1782952257.xml · nonDerivative · entry 1 Asarpota Rajesh · CIK 0001600301 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 434,416 F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock unit awards held by the reporting person. Read SEC document |
| January 26, 2026 Filed Jan 29, 2026 02:06 UTC | Profusa, Inc. PFSA · Entity 2740 | GrantStock Options · Derivative | 52,866 | $0.00 Strike: $0.35 | $0.00 |
DisclosureSEC source: 0001213900-26-009033 · ownership.xml · derivative · entry 2 Asarpota Rajesh · CIK 0001600301 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,866 Underlying: Common Stock · 52,866 shares Expires 2036-01-26 F2 · shares: Represents an annual director award of options to purchase common stock. The options vest on the first anniversary of the Closing. Read SEC document |
| January 26, 2026 Filed Jan 29, 2026 02:06 UTC | Profusa, Inc. PFSA · Entity 2740 | GrantStock Options · Derivative | 221,794 | $0.00 Strike: $0.35 | $0.00 |
DisclosureSEC source: 0001213900-26-009033 · ownership.xml · derivative · entry 1 Asarpota Rajesh · CIK 0001600301 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 221,794 Underlying: Common Stock · 221,794 shares Expires 2036-01-26 F1 · shares: Represents an inaugural director award of options to purchase common stock. The options vest in three equal annual increments over a period of three years from the closing of the business combination between the Issuer (formerly known as NorthView Acquisition Corp.) and Profusa, Inc. (the "Closing"). Read SEC document |
| June 30, 2025 Filed Jun 30, 2025 22:04 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | GrantPerformance Stock Units · Derivative | 750,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001823239-25-000093 · wk-form4_1751321084.xml · derivative · entry 3 Asarpota Rajesh · CIK 0001600301 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 750,000 Underlying: Class A Common Stock · 750,000 shares Expires 2028-07-30 F3 · derivative.exercise_price: Represents performance-based restricted stock units ("PSUs") awarded under the Omnibus Incentive Plan. Each PSU represents the contingent right to receive one share of Class A Common Stock of the Issuer. The PSUs will vest if and to the extent the volume-weighted average price of a share of the Class A Common Stock of the Issuer equals or exceeds certain thresholds for the 30 consecutive trading days immediately preceding the third anniversary of the grant date, subject to the Reporting Person's continued employment with the Issuer (except as otherwise provided in connection with certain circumstances as set forth in the award agreement). F3 · derivative.exercise_date: Represents performance-based restricted stock units ("PSUs") awarded under the Omnibus Incentive Plan. Each PSU represents the contingent right to receive one share of Class A Common Stock of the Issuer. The PSUs will vest if and to the extent the volume-weighted average price of a share of the Class A Common Stock of the Issuer equals or exceeds certain thresholds for the 30 consecutive trading days immediately preceding the third anniversary of the grant date, subject to the Reporting Person's continued employment with the Issuer (except as otherwise provided in connection with certain circumstances as set forth in the award agreement). Read SEC document |
| June 30, 2025 Filed Jun 30, 2025 22:04 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | GrantEmployee Stock Option (Right to Buy) · Derivative | 333,333 | $0.00 Strike: $2.41 | $0.00 |
DisclosureSEC source: 0001823239-25-000093 · wk-form4_1751321084.xml · derivative · entry 2 Asarpota Rajesh · CIK 0001600301 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 333,333 Underlying: Class A Common Stock · 333,333 shares Expires 2035-06-30 F2 · derivative.exercise_date: Represents options awarded under the Omnibus Incentive Plan. These options vest over a three-year period, with one-third of the options vesting on the first anniversary of the grant date and the remaining two-thirds of the options vesting in 24 substantially equal monthly installments, subject to the Reporting Person's continued employment with the Issuer (except as otherwise provided in connection with certain circumstances as set forth in the award agreement). Read SEC document |
| June 30, 2025 Filed Jun 30, 2025 22:04 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | GrantClass A Common Stock | 500,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001823239-25-000093 · wk-form4_1751321084.xml · nonDerivative · entry 1 Asarpota Rajesh · CIK 0001600301 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 F1 · price: Represents restricted stock units ("RSUs") awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan (the "Omnibus Incentive Plan"). Each RSU represents the right to receive one share of Class A Common Stock of the Issuer upon vesting. The RSUs vest over a three-year period, with one-third of the RSUs vesting on the first anniversary of the grant date and the remaining two-thirds of the RSUs vesting in 24 substantially equal monthly installments, subject to the Reporting Person's continued employment with the Issuer (except as otherwise provided in connection with certain circumstances as set forth in the award agreement). Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 17:50 UTC | NUVASIVE INC NUVA · Entity 110002 | GrantRSUs · Derivative | 12,398 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-016834 · doc4.xml · derivative · entry 1 Asarpota Rajesh · CIK 0001600301 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,398 Underlying: Common Stock · 12,398 shares Expires not disclosed F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: This RSU award was granted to the Reporting Person on March 1, 2019. In accordance with the terms of the RSU award, the award will vest in full on March 1, 2022. F2 · derivative.expiration_date: This RSU award was granted to the Reporting Person on March 1, 2019. In accordance with the terms of the RSU award, the award will vest in full on March 1, 2022. Read SEC document |
| February 06, 2019 Filed Feb 7, 2019 17:47 UTC | NUVASIVE INC NUVA · Entity 110002 | GrantPRSUs · Derivative | 11,277 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008185 · doc4.xml · derivative · entry 1 Asarpota Rajesh · CIK 0001600301 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,277 Underlying: Common Stock · 11,277 shares Expires not disclosed F1 · security: Each Performance Restricted Stock Unit ("PRSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: This PRSU award was granted to the Reporting Person on April 30, 2018. The award was granted with a performance condition based on the Issuer's earnings per share over the performance period ended December 31, 2018. On February 6, 2019, the Compensation Committee of the Issuer's Board of Directors certified the Issuer's performance for purposes of the award. Based on the Issuer's performance, the award will vest as to 11,277 shares on April 30, 2021, subject to and in accordance with the terms of the award. As the award did not constitute a derivative security, it was not required to be reported and was not reported on a Form 4 at the time of grant. F2 · derivative.expiration_date: This PRSU award was granted to the Reporting Person on April 30, 2018. The award was granted with a performance condition based on the Issuer's earnings per share over the performance period ended December 31, 2018. On February 6, 2019, the Compensation Committee of the Issuer's Board of Directors certified the Issuer's performance for purposes of the award. Based on the Issuer's performance, the award will vest as to 11,277 shares on April 30, 2021, subject to and in accordance with the terms of the award. As the award did not constitute a derivative security, it was not required to be reported and was not reported on a Form 4 at the time of grant. Read SEC document |
| February 07, 2018 Filed Feb 7, 2019 17:45 UTC | NUVASIVE INC NUVA · Entity 110002 | GrantPRSUs · Derivative | 11,242 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008181 · doc5.xml · derivative · entry 1 Asarpota Rajesh · CIK 0001600301 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,242 Underlying: Common Stock · 11,242 shares Expires not disclosed F1 · security: Each Performance Restricted Stock Unit ("PRSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: This PRSU award was granted to the Reporting Person on September 1, 2017. The award was granted with a performance condition based on the Issuer's earnings per share over the performance period ended December 31, 2017. On February 7, 2018, the Compensation Committee of the Issuer's Board of Directors certified the Issuer's performance for purposes of the award. Based on the Issuer's performance, the award will vest as to 11,242 shares on September 1, 2020, subject to and in accordance with the terms of the award. As the award did not constitute a derivative security, it was not required to be reported and was not reported on a Form 4 at the time grant. Due to an administrative error, a Form 4 reporting the certification of the performance condition was not filed in February 2018. F2 · derivative.expiration_date: This PRSU award was granted to the Reporting Person on September 1, 2017. The award was granted with a performance condition based on the Issuer's earnings per share over the performance period ended December 31, 2017. On February 7, 2018, the Compensation Committee of the Issuer's Board of Directors certified the Issuer's performance for purposes of the award. Based on the Issuer's performance, the award will vest as to 11,242 shares on September 1, 2020, subject to and in accordance with the terms of the award. As the award did not constitute a derivative security, it was not required to be reported and was not reported on a Form 4 at the time grant. Due to an administrative error, a Form 4 reporting the certification of the performance condition was not filed in February 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.